51成人动漫

Crystal Phend

Crystal Phend

Authors >

Crystal Phend

Crystal Phend is a contributing editor with 51成人动漫, where she's been covering medical news of all stripes since 2006.

Connect:

email image

Latest from Crystal Phend

A photo of a box and vial of Tzield for injection.

Antibody Slows Beta-Cell Loss Early in Type 1 Diabetes

PROTECT trial may expand the biologic's use into a larger pool of recently diagnosed patients

ECTRIMS over a photo of the Milano Convention Center in Milano Congressi, Italy.

Clinical Challenges: Determining When to Stop MS Therapy as Patients Age

DISCOMS trial has provided data to guide decisions, now it's all about individualized discussions

A computer rendering of a ruptured artery.

Cryoprecipitate, REBOA Flop for Improving Major Hemorrhage Outcomes

The first randomized trials of both approaches failed

HFSA over a photo of Huntington Convention Center in Cleveland, Ohio.

Novel Nerve Ablation Procedure Explored for HFpEF

Splanchnic nerve ablation for volume management passes a feasibility hurdle

HFSA over a photo of Huntington Convention Center in Cleveland, Ohio.

Copper-Boosting Agent Promising for Low Ejection Fraction Heart Failure

Early-phase study analysis suggests potential for remodeling

HFSA over a photo of Huntington Convention Center in Cleveland, Ohio.

Modest Risks Come With Moving Fast on HF Drugs After Acute Event

STRONG-HF analysis details the impact

HFSA over a photo of Huntington Convention Center in Cleveland, Ohio.

Vagus Nerve Stimulation in Limbo for HFrEF

Autonomic regulation therapy trial showed signal for benefit in terminated pivotal trial

HFSA over a photo of Huntington Convention Center in Cleveland, Ohio.

Biomarker-Based CardioMEMS Candidates Still Benefit

GUIDE-HF trial analysis distinguishes "strata" with different levels of risk

HFSA over a photo of Huntington Convention Center in Cleveland, Ohio.

FDA Turns Down ATTR Cardiomyopathy Drug

Decision cites insufficient evidence of clinical meaningfulness

Illustration of human head with brain activity.

Novel Agent Promising as Add-On Epilepsy Treatment

Phase IIb trial shows benefit for the most common type of epileptic seizures

鈥�

15

鈥�